Letter to the Editor: Re: “Life Years Gained From the FDA Accelerated Approval Program in Oncology: A Portfolio Model”
Journal of the National Comprehensive Cancer Network · 2024
DOI: 10.6004/jnccn.2024.7043 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2024. Verfasst von Ian T T Liu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Program on Regulation, Therapeutics and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hosp…. Hauptthemen laut MEDLINE: United States Food and Drug Administration, Drug Approval, Medical Oncology. Die Arbeit nennt 4 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Program on Regulation, Therapeutics and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
Zitieren
APA
Liu, I. T. T., & Kesselheim, A. S. (2024). Letter to the Editor: Re: “Life Years Gained From the FDA Accelerated Approval Program in Oncology: A Portfolio Model”. Journal of the National Comprehensive Cancer Network. https://doi.org/10.6004/jnccn.2024.7043
Vancouver
Liu ITT, Kesselheim AS. Letter to the Editor: Re: “Life Years Gained From the FDA Accelerated Approval Program in Oncology: A Portfolio Model”. Journal of the National Comprehensive Cancer Network. 2024. doi:10.6004/jnccn.2024.7043
BibTeX
@article{Liu2024,
author = {Liu, Ian T T and Kesselheim, Aaron S},
title = {Letter to the Editor: Re: “Life Years Gained From the FDA Accelerated Approval Program in Oncology: A Portfolio Model”},
journal = {Journal of the National Comprehensive Cancer Network},
year = {2024},
doi = {10.6004/jnccn.2024.7043}
}
EUVIMED